News & Events
Company Profile
Provectus today announced that data from an ongoing clinical trial of investigational cancer immunotherapy PV-10 for the treatment of uveal melanoma metastatic to the liver will be presented at the 20th Congress of the International Society of Ocular Oncology, to be held June 17-21, 2022 in Leiden, The Netherlands.
Analyst Opinions
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor…
Research Reports
The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....
0.0 Analyst's Opinion
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
How has Provectus Biopharmaceuticals' stock price been impacted by COVID-19?
Provectus Biopharmaceuticals has received 84 “outperform” votes. (Add your “outperform” vote.)
Are investors shorting Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals' stock was trading at $0.0445 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, PVCT shares have increased by 53.5% and is now trading at $0.0683. View which stocks have been most impacted by COVID-19.
Who are some of Provectus Biopharmaceuticals' key competitors?
Provectus Biopharmaceuticals saw a decrease in short interest during the month of January. As of January 31st, there was short interest totaling 7,700 shares, a decrease of 85.4% from the January 15th total of 52,600 shares.
What other stocks do shareholders of Provectus Biopharmaceuticals own?
Some companies that are related to Provectus Biopharmaceuticals include Reneo Pharmaceuticals (RPHM), Otonomy (OTIC), Seelos Therapeutics (SEEL), Sensei Biotherapeutics (SNSE), RedHill Biopharma (RDHL), Equillium (EQ), Actinium Pharmaceuticals (ATNM), 180 Life Sciences (ATNF), Gelesis (GLS), Capricor Therapeutics (CAPR), Genprex (GNPX), Viracta Therapeutics (VIRX), Alzamend Neuro (ALZN), Lipocine (LPCN) and SCYNEXIS (SCYX). View all of PVCT's competitors..
What is Provectus Biopharmaceuticals' stock symbol?
Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc.
How do I buy shares of Provectus Biopharmaceuticals?
Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."
